Interim Guidelines for the Clinical Management of Diabetes in Jamaica

Objectives

Provide interim, nationally relevant clinical updates for diabetes care in Jamaica while the Ministry of Health and Wellness undertakes a comprehensive revision of the national guidelines, responding to a rising burden of diabetes, mortality, chronic complications and inadequate control among people receiving treatment.[1][2]The overarching clinical purpose is to eliminate symptoms and prevent or reduce complications through accurate diagnosis, individualised treatment, near-normal glycaemic control, management of blood lipids and blood pressure, lifestyle change, medicines and self-monitoring.[3][4][5]

• Strengthen diagnosis and classification of diabetes, impaired glucose tolerance, impaired fasting glucose and gestational diabetes using glucose-based testing, while recognising limitations of glycated haemoglobin in screening and diagnosis.[6][7]
• Identify metabolic risk factors, including abdominal obesity, raised triglycerides, low high-density lipoprotein cholesterol, hypertension and raised fasting glucose, to address diabetes risk and associated chronic complications.[3]
• Prevent complications through comprehensive assessment, ongoing monitoring, screening for eye, foot, renal, cardiovascular and metabolic complications, and timely specialist referral.[4][5][8]
• Optimise staged treatment for adults with type 2 diabetes, including metformin where appropriate, additional glucose-lowering medicines and insulin-based regimens when agreed glycated haemoglobin targets are not achieved.[5][9]
• Provide appropriate insulin regimens for type 1 and type 2 diabetes, guided by glycaemic targets, hypoglycaemia risk, tolerability, patient preference, lifestyle needs and, where applicable, acquisition cost.[10][11]
• Enable safe self-management during illness, exercise, pregnancy-related circumstances and routine home glucose monitoring, and extend access to care through secure, clinically appropriate telehealth.[12][13][14]

Implementation

Deliver diabetes care through structured clinical assessment, laboratory diagnosis, individualised pharmacological and non-pharmacological management, self-management support, multidisciplinary referral and documented remote consultations where suitable.[6][4][9][15]The Ministry of Health and Wellness issues the guidance, with preparation support from the Association of Consultant Physicians of Jamaica; the supplied material does not define a wider programme governance structure or formal service-delivery model.[1][3]

• Assess each person comprehensively, covering disease onset, eating and activity patterns, weight, comorbidities, psychosocial and dental needs, treatment response, adherence, glucose records, hypoglycaemia, ketoacidosis and diabetes-related complications.[7][4]
• Use fasting plasma glucose, a two-hour post-75-gram glucose challenge, oral glucose tolerance testing and random glucose in symptomatic people as appropriate, and use laboratory methods that account for haemoglobinopathies or altered erythrocyte turnover.[6]
• Undertake relevant laboratory evaluation, including glucose profiles, glycated haemoglobin where available, lipid profile, liver and renal assessment, urine ketones, and selected thyroid and beta-cell antibody tests.[4]
• Monitor blood pressure at every visit and use glycated haemoglobin, renal function and estimated glomerular filtration rate to guide medicine choice and treatment intensification.[5][9]
• Initiate insulin through a structured programme covering injection technique, self-monitoring, dose titration, dietary understanding, driving advice, hypoglycaemia management and continuing support from trained health professionals.[9]
• Refer people to eye-care professionals, dietitians, dental and mental-health professionals where needed, and arrange specialist care for serious acute or chronic complications, including diabetic ketoacidosis, hyperosmolar hyperglycaemic states, chronic kidney disease, heart failure, myocardial infarction and stroke with dysphagia requiring tube feeding.[4][12]
• Provide eye examination at diagnosis and annual structured screening thereafter, maintain foot-care surveillance for people at elevated risk, and use albuminuria and estimated glomerular filtration rate to guide kidney-risk assessment and nephrology referral.[8]
• Support sick-day care by maintaining insulin and most suitable medicines, stopping sodium-glucose co-transporter 2 inhibitors, increasing glucose monitoring, checking ketones for type 1 diabetes, maintaining hydration and seeking care for persistent vomiting or inability to retain fluids.[12]
• Support exercise safely through glucose monitoring before and after activity, adjustment of insulin or food intake where needed, and access to carbohydrate-rich food to address actual or delayed hypoglycaemia.[12][8]
• Provide routine self-monitoring of blood glucose for adults with type 1 diabetes and selective, clinically indicated monitoring for adults with type 2 diabetes, with at least annual structured review of monitoring skills, frequency, interpretation, benefit and equipment for type 2 diabetes.[13]
• Use telehealth for suitable, preferably known regular patients with available records following telephone triage and informed consent; convert to face-to-face care when examination is necessary, records are unavailable, confidentiality or technical problems occur, or the patient is clinically unstable.[14][15]
• Document remote encounters to the standard of face-to-face consultations, record telehealth delivery and consent, protect communications and devices through secure technology, passwords and encryption, and document any onward referral, clinician and urgency.[14][16]

Monitoring & Evaluation

Monitoring is principally embedded in clinical care, using population burden measures, diagnostic standards, regular assessment of metabolic control, complication screening, treatment review, self-management checks, and documentation of telehealth encounters. The extract does not set out a unified programme-level evaluation framework, routine reporting cycle, surveillance system, or named accountability mechanism.[1][2][16]

• Track diabetes mortality, prevalence, treatment coverage, and the proportion of treated people achieving control. In Jamaica, diabetes accounted for 2,339 deaths, or 12.7% of all deaths, in 2016; prevalence among people aged 15 to 74 years rose by 41.1% between 2001 and 2017; and approximately 27.5% of people receiving treatment were controlled in 2016 to 2017.[2]
• Apply diagnostic standards based on fasting plasma glucose, two-hour post-75-gram glucose challenge testing, and random blood glucose where osmotic symptoms are present; use oral glucose tolerance testing for impaired glucose tolerance.[6]
• Use glycated haemoglobin assays certified by the National Glycohemoglobin Standardization Programme and traceable to the Diabetes Control and Complications Trial reference, while accounting for haemoglobinopathies and conditions affecting erythrocyte turnover.[6]
• Monitor blood glucose, lipids, blood pressure, treatment response, medication adherence, hypoglycaemia, and diabetes-related complications during continuing clinical assessment.[3][7][4]
• Measure blood pressure at every visit and use glycated haemoglobin control and renal function, including estimated glomerular filtration rate, to guide pharmacological treatment and intensification.[4][5][9]
• Screen for retinopathy, foot complications, lipid abnormalities, albuminuria, blood-pressure abnormalities, and electrocardiographic abnormalities in type 2 diabetes, with timing determined by diabetes type, duration, clinical severity, and indication.[4][5]
• Review insulin regimens against agreed glycaemic targets, tolerability, acceptability, and the need to add mealtime insulin or convert from premixed to basal-bolus treatment when control is inadequate.[10][11]
• Monitor blood glucose at least every four hours during sick days for people using insulin, and before and after exercise, to identify dietary or treatment adjustments and detect immediate or delayed hypoglycaemia.[12][8]
• Undertake annual structured eye screening after the initial comprehensive eye examination, and use estimated glomerular filtration rate and albuminuria to assess chronic kidney disease risk, determine follow-up frequency, and guide nephrology referral.[8]
• Conduct at least annual structured assessments for adults with type 2 diabetes who self-monitor blood glucose, covering testing skills, quality and frequency, interpretation and response to results, quality-of-life effects, continuing benefit, and equipment.[13]
• Document telehealth consultations to the standard of face-to-face care, including relevant history, observations or examination, decision-making information, and advice. Record telehealth delivery and obtain consent before recording telephone or video interactions; any recording forms part of the patient record.[16]

Costing & Financing

No quantified costs, budget, funding allocation, resource-mobilisation plan, funding gap, or economic assumption is provided in the supplied extracts. Cost is nevertheless identified as one factor in selecting certain insulin regimens, while telehealth delivery requires consideration of insurance coverage, billing, technology, and administrative support.[10][14][15]

• Consider acquisition cost alongside glycaemic targets, tolerability, acceptability, and patient preference when selecting alternative insulin regimens for adults with type 1 diabetes.[10][11]
• Recognise that fasting plasma glucose testing is described as cheaper and more convenient than the two-hour post-challenge test, although no monetary amount or comparative cost is supplied.[6]
• Verify health-insurance reimbursement for telehealth consultations, including whether consultations are covered at in-office rates; no reimbursement value or financing arrangement is specified.[14]
• Confirm insurance details for telehealth billing and use time-based billing where applicable, without stated fees, budgets, or payment rates.[15]
• Resource remote care through secure technology and networks, video-consultation capability, protected devices, electronic prescribing and diagnostic ordering where appropriate, and administrative or medical-assistant support for scheduling, technical checks, insurance information, records, medicines, allergies, and home vital signs.[14][15]
• Recognise that the extracts do not quantify the costs of laboratory testing, medicines, insulin, self-monitoring equipment, screening, referrals, telehealth infrastructure, staff, or specialist services.[7][4][13][16]